AstraZeneca: to buy priority review voucher from Sobi
(CercleFinance.com) - AstraZeneca today announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of 95 million dollars from a subsidiary of Sobi.
The purchase of this PRV will enable the Anglo-Swedish biopharmaceutical group to benefit from a reduced target review time (around six months), for one of its future drug registration dossiers, instead of the usual 10 months.
Since 2007, PRVs granted by FDA and are transferable and may be assigned and used by any other company.
On Thursday AstraZeneca also announced the approval, in China, of Roxadustat, a treatment for anemia in patients with chronic kidney disease without dialysis.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The purchase of this PRV will enable the Anglo-Swedish biopharmaceutical group to benefit from a reduced target review time (around six months), for one of its future drug registration dossiers, instead of the usual 10 months.
Since 2007, PRVs granted by FDA and are transferable and may be assigned and used by any other company.
On Thursday AstraZeneca also announced the approval, in China, of Roxadustat, a treatment for anemia in patients with chronic kidney disease without dialysis.
Copyright (c) 2019 CercleFinance.com. All rights reserved.